Can selective serotonin reuptake inhibitors have a neuroprotective effect during COVID-19?

The absence of a specific treatment for SARS-CoV-2 infection led to an intense global effort in order to find new therapeutic interventions and improve patient outcomes. One important feature of COVID-19 pathophysiology is the activation of immune cells, with consequent massive production and releas...

Descripción completa

Detalles Bibliográficos
Autores principales: Costa, Luis H.A., Santos, Bruna M., Branco, Luiz G.S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2020
Materias:
Full Length Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832208/
https://www.ncbi.nlm.nih.gov/pubmed/33022271
http://dx.doi.org/10.1016/j.ejphar.2020.173629

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7832208/
https://www.ncbi.nlm.nih.gov/pubmed/33022271
http://dx.doi.org/10.1016/j.ejphar.2020.173629

Ejemplares similares